These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2653519)

  • 1. Mitoxantrone and amsacrine: two important agents for the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL).
    Arlin ZA
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():57-9. PubMed ID: 2653519
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy of relapsed AML and ALL].
    Nishikawa K
    Rinsho Ketsueki; 1996 Aug; 37(8):647-50. PubMed ID: 8827871
    [No Abstract]   [Full Text] [Related]  

  • 4. A special role for amsacrine in the treatment of acute leukemia.
    Arlin ZA
    Cancer Invest; 1989; 7(6):607-9. PubMed ID: 2630010
    [No Abstract]   [Full Text] [Related]  

  • 5. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 6. Induction chemotherapy for acute myelogenous leukemia.
    Kalaycio M
    Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: 15610659
    [No Abstract]   [Full Text] [Related]  

  • 7. Mitoxantrone for refractory and relapsed acute leukemia.
    Bezwoda WR; Bernasconi C; Hutchinson RM; Winfield DA; de Bock R; Mandelli F
    Cancer; 1990 Aug; 66(3):418-22. PubMed ID: 2194640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs in acute myelogenous leukemia: a review.
    Berman E
    J Clin Pharmacol; 1992 Apr; 32(4):296-309. PubMed ID: 1569232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
    Lobato-Mendizábal E; Ruiz-Argüelles GJ; Marín-López A
    Rev Invest Clin; 1989; 41(2):139-45. PubMed ID: 2675236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status of complete remission rate of acute leukemia in Shanghai].
    Shanghai Leukemia Cooperative Group Shanghai 200040 China
    Zhonghua Xue Ye Xue Za Zhi; 2000 Jan; 21(1):17-9. PubMed ID: 11876954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amsacrine: a review.
    Cassileth PA; Gale RP
    Leuk Res; 1986; 10(11):1257-65. PubMed ID: 3540460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of therapy and prognosis in acute adult leukemia].
    Gmür J
    Ther Umsch; 1996 Feb; 53(2):111-6. PubMed ID: 8629260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myeloid and lymphoblastic leukemia in adults. The course of the disease in 315 patients from one region, during a ten-year period.
    Johnsen HE; Bergmann OJ; Ellegaard J; Bastrup-Madsen P
    Dan Med Bull; 1989 Apr; 36(2):189-93. PubMed ID: 2707057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigations in the use of mogramostime (GM-CSF) in patients with acute leukemia].
    Paśnicki M
    Wiad Lek; 1995; 48(1-12):194-7. PubMed ID: 9638239
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous-infusion amsacrine in patients with refractory acute myelogenous leukemia.
    Estey EH; Keating MJ; McCredie KB; Freireich EJ
    Cancer Treat Rep; 1987 Nov; 71(11):1113-4. PubMed ID: 3119207
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of idarubicin in acute leukemia.
    Berman E
    Oncology (Williston Park); 1993 Oct; 7(10):91-8, 104; discussion 104-7. PubMed ID: 8251309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of acute leukemia in adults].
    Elonen E
    Duodecim; 1989; 105(11):987-93. PubMed ID: 2666099
    [No Abstract]   [Full Text] [Related]  

  • 20. [Retrospective study of acute myelogenous leukemia in elderly patients: treatment and outcome of 83 consecutive patients].
    Ino T; Tsuzuki M; Hasegawa A; Miyazaki H; Kojima H; Maruyama F; Okamoto M; Matsui T; Ezaki K; Hirano M
    Rinsho Ketsueki; 2000 Apr; 41(4):303-9. PubMed ID: 10846460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.